Reinach, Switzerland

Karl-Heinz Altmann

USPTO Granted Patents = 23 

 

Average Co-Inventor Count = 3.7

ph-index = 12

Forward Citations = 1,297(Granted Patents)


Location History:

  • Basel, CH (1995 - 1997)
  • Reinach, CH (1998 - 2010)

Company Filing History:


Years Active: 1995-2010

Loading Chart...
Loading Chart...
23 patents (USPTO):Explore Patents

Title: Contributions of Karl-Heinz Altmann to Pharmaceutical Innovation

Introduction

Karl-Heinz Altmann, based in Reinach, Switzerland, is a prominent inventor with a significant portfolio of 23 patents. His work primarily focuses on advancements in pharmaceuticals, particularly in the field of cancer treatment. His innovative contributions have made him a notable figure in the scientific community.

Latest Patents

Altmann's recent patents include groundbreaking work on Epothilone derivatives, which are vital for their use as a pharmaceutical. These compounds have shown promising results in promoting tubulin polymerization and serving as cytotoxic agents in the treatment of neoplastic diseases. Another recent patent pertains to cyclopropyl and cyclobutyl epothilone analogs, where he explores the synthesis and biological evaluation of these compounds, which possess significant therapeutic potential.

Career Highlights

Throughout his career, Altmann has held key positions at renowned companies, including Novartis AG and Isis Pharmaceuticals, Inc. His experience in these organizations has enabled him to contribute extensively to pharmaceutical research and development, culminating in a series of impactful inventions that enhance treatment options for cancer patients.

Collaborations

Karl-Heinz Altmann has collaborated with distinguished colleagues such as Guido Bold and Pierre Martin. These partnerships have facilitated a robust exchange of ideas and expertise, further advancing his research and leading to successful patent applications.

Conclusion

In summary, Karl-Heinz Altmann’s contributions to the pharmaceutical industry are marked by his extensive patent portfolio and innovative research. His latest work on epothilone derivatives and related compounds demonstrates his commitment to developing effective cancer treatments. As he continues to push the boundaries of scientific discovery, his efforts remain influential in the ongoing fight against neoplastic diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…